CN
  • Jan Completed series C+ round fundraising
    Mar Received IND approval from NMPA for AK3280 phase II trial in China
    Apr Initiated ziresovir's phase I study in the US
    2021
  • Jul Out-licensed AK0706's China rights to Amoytop
    Oct Ziresovir received breakthrough designation by NMPA
    Nov Awarded gold medal in innovation competition by National Health Commission of China for the development of ziresovir
    Dec Completed series C round fundraising
    2020
  • Jan Presented at J.P. Morgan 37th Healthcare Conference
    Oct Initiated AK3280 phase Ib study in Sweden
    Dec Ziresovir received approval from NMPA for phase III registration trial
    2019
  • July Completed series B round fundraising
    Aug In-licensed AK3280 global rights from Genentech/Intermune/Roche
    2018
  • Oct Completed ziresovir's first Chinese adult dosing
    Nov Partnered with Calibr for COPD drug
    2017
  • May Established our Suzhou R&D Center
    Jul Completed ziresovir's first infant dosing
    Sept Completed series A+ round fundraising
    2016
  • Mar Completed series A fundraising
    Sept Completed ziresovir FIH clinical trial in Australia
    2015
  • Jan In-licensed ziresovir global rights from Roche
    Completed ziresovir FIH dosing
    2014
  • Aug Ark founded in Zhangjiang Hitech Park in Shanghai
    Dec Completed angel round of fundraising
    2013
Expand
MORE
TOP

About Us

Research

Pipeline

Media

Career

Contact Us

Investor relations

Telephone：
+86 21 50681677
Address：
Building 25, Lane 388, Shengrong Road, Pudong, Shanghai 201203, China
E-mail：
info@arkbiosciences.com
Official Account
  • Home
  • Tel
  • Top